CNBX Pharmaceuticals Inc CNBX:OTCQB

*Data is delayed | Exchange | USD
Last | 05/20/24 EDT
0.011UNCH (UNCH)
52 week range
0.01 - 0.05
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.011
  • 52 Week High0.05
  • 52 Week High Date09/13/23
  • 52 Week Low0.01
  • 52 Week Low Date05/14/24

Key Stats

  • Market Cap342,224.836
  • Shares Out31.11M
  • 10 Day Average Volume312,213.1
  • Dividend-
  • Dividend Yield-
  • Beta0.83
  • YTD % Change-22.54

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.011
  • 52 Week High0.05
  • 52 Week High Date09/13/23
  • 52 Week Low0.01
  • 52 Week Low Date05/14/24
  • Market Cap342,224.836
  • Shares Out31.11M
  • 10 Day Average Volume312,213.1
  • Dividend-
  • Dividend Yield-
  • Beta0.83
  • YTD % Change-22.54

RATIOS/PROFITABILITY

  • EPS (TTM)-0.06
  • P/E (TTM)-0.19
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-562,110.007
  • ROE (TTM)-4,289.21%
  • Revenue (TTM)540,250.003
  • Gross Margin (TTM)6.37%
  • Net Margin (TTM)-228.08%
  • Debt To Equity (MRQ)-54.80%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On CNBX Pharmaceuticals Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
CNBX Pharmaceuticals Inc. is a clinical-stage company specializing in the discovery, development and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The Company's lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy...
Gabriel Yariv
Executive Chairman of the Board
Eyal Barad
Chief Executive Officer, Director
Uri Ben-Or CPA
Chief Financial Officer
Sanja Goldberg
Chief Technology Officer
Address
#3 Bethesda Metro Center, Suite 700
Bethesda, MD
20814
United States